{"filing":{"accession_number":"0001104659-26-078865","cik":"0001082554","ticker":"UTHR","company_name":"UNITED THERAPEUTICS Corp","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tm2619258d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465926078865/tm2619258d1_8k.htm"},"events":[{"id":14691,"run_id":13085,"accession_number":"0001104659-26-078865","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"United Therapeutics held its Annual Meeting of Shareholders on June 26, 2026, with shareholders voting on four matters: election of 11 directors, advisory vote on executive compensation, approval of the 2026 Stock Incentive Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing discloses the detailed vote tallies for each matter.","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12194,"accession_number":"0001104659-26-078865","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure describes shareholder approval of the United Therapeutics Corporation 2026 Stock Incentive Plan, which establishes a new equity compensation framework allowing grants of stock options, restricted stock, restricted stock units, and performance-based awards to directors, officers, employees, and service providers. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The plan's adoption and the authorization of 1.5 million new shares plus rollover of remaining shares from the prior plan represent a material change to the company's equity compensation structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:35:14.096329+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12195,"accession_number":"0001104659-26-078865","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the June 26, 2026 Annual Meeting of Shareholders, covering four matters: election of 11 directors, advisory vote on executive compensation, approval of the 2026 Stock Incentive Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies for each matter are the core content of Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:35:14.096329+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12194,"accession_number":"0001104659-26-078865","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure describes shareholder approval of the United Therapeutics Corporation 2026 Stock Incentive Plan, which establishes a new equity compensation framework allowing grants of stock options, restricted stock, restricted stock units, and performance-based awards to directors, officers, employees, and service providers. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an executive departure or appointment. The plan's adoption and the authorization of 1.5 million new shares plus rollover of remaining shares from the prior plan represent a material change to the company's equity compensation structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:35:14.096329+00:00","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-06-29"},{"id":12195,"accession_number":"0001104659-26-078865","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the June 26, 2026 Annual Meeting of Shareholders, covering four matters: election of 11 directors, advisory vote on executive compensation, approval of the 2026 Stock Incentive Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies for each matter are the core content of Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:35:14.096329+00:00","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-06-29"}]}